US 12,139,494 B2
Morphic forms of G1T38 and methods of manufacture thereof
Alexander Smith, Apex, NC (US); Hannah S. White, Chapel Hill, NC (US); Patricia Andres, Bend, OR (US); Xufeng Sun, Albany, NY (US); Lei Zhu, Schenectady, NY (US); and Petinka I. Vlahova, West Lafayette, IN (US)
Assigned to G1 Therapeutics, Inc.
Filed by G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed on Feb. 28, 2022, as Appl. No. 17/683,146.
Application 17/683,146 is a continuation of application No. 16/721,631, filed on Dec. 19, 2019, granted, now 11,261,193.
Application 16/721,631 is a continuation of application No. PCT/US2018/040435, filed on Jun. 29, 2018.
Claims priority of provisional application 62/526,937, filed on Jun. 29, 2017.
Prior Publication US 2023/0043305 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 45/06 (2006.01); C07D 487/14 (2006.01)
CPC C07D 487/14 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 1 Claim
 
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient for solid dosage delivery and between about 10 mg and about 1,000 mg of an isolated crystalline Form B of the di-HCl salt of structure:

OG Complex Work Unit Chemistry
characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three 2θ values selected from 6.5±0.2°, 9.5±0.4°, 14.0±0.2°, 14.4±0.2°, 18.1±0.2°, 19.3±0.2°, 19.9±0.2°, and 22.4±0.2°.